Stay updated on VenDex vs PomDex in t(11;14)+ MM Clinical Trial
Sign up to get notified when there's something new on the VenDex vs PomDex in t(11;14)+ MM Clinical Trial page.

Latest updates to the VenDex vs PomDex in t(11;14)+ MM Clinical Trial page
- Check6 days agoNo Change Detected
- Check14 days agoChange DetectedDeleted the term 'Multiple myeloma' from the page and removed the 'MedlinePlus Genetics' related topics link.SummaryDifference0.1%

- Check21 days agoChange DetectedRevision: v3.5.0 was added to the page, replacing the previous Revision: v3.4.3 label.SummaryDifference0.0%

- Check28 days agoNo Change Detected
- Check35 days agoChange DetectedAdded related topics 'Multiple myeloma' and 'MedlinePlus Genetics' and updated the page revision from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check57 days agoChange DetectedCANOVA primary results publication added: Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-positive relapsed or refractory MM published in J Clin Oncol (2026; 44(3):164-175; DOI: 10.1200/JCO-25-00924; Epub 2025-12-10). The earlier ahead-of-print citation was replaced with the updated JCO citation.SummaryDifference0.0%

- Check64 days agoChange DetectedA small update to the site's revision history was made, adding Revision: v3.4.1 and removing Revision: v3.4.0, reflecting internal version control rather than changes to study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check71 days agoChange DetectedRemoved 'Multiple Myeloma' and 'MedlinePlus Genetics' from the study page's related topics/keywords. This change removes metadata without altering core trial content or patient information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to VenDex vs PomDex in t(11;14)+ MM Clinical Trial
Enter your email address, and we'll notify you when there's something new on the VenDex vs PomDex in t(11;14)+ MM Clinical Trial page.